171 related articles for article (PubMed ID: 38181784)
1. In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation.
Leonard AK; Furstenau D; Inam Z; Luckett C; Chu R; Demirci S; Essawi K; Gudmundsdottir B; Hinds M; DiNicola J; Li Q; Eaton WA; Cellmer T; Wang X; Thein SL; Macari ER; VanNest S; Hsieh MM; Bonner M; Pierciey FJ; Tisdale JF
Blood Adv; 2024 Apr; 8(7):1806-1816. PubMed ID: 38181784
[TBL] [Abstract][Full Text] [Related]
2. The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study.
Nickel RS; Flegel WA; Adams SD; Hendrickson JE; Liang H; Tisdale JF; Hsieh MM
EClinicalMedicine; 2020 Jul; 24():100432. PubMed ID: 32637902
[TBL] [Abstract][Full Text] [Related]
3. Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: A review of current and future methods.
Lewis J; Greenway SC; Khan F; Singh G; Bhatia M; Guilcher GMT
Am J Hematol; 2022 Oct; 97(10):1359-1371. PubMed ID: 35583381
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Effects of Allogeneic Hematopoietic Stem Cell Transplantation on Systemic Inflammation in Sickle Cell Disease Patients.
de Azevedo JTC; Costa TCM; Lima KC; Maciel TT; Palma PVB; Darrigo-Júnior LG; Setanni Grecco CE; Stracieri ABPL; Elias JB; Pieroni F; Guerino-Cunha RL; Pinto ACS; De Santis GC; Covas DT; Hermine O; Simões BP; Oliveira MC; Malmegrim KCR
Front Immunol; 2021; 12():774442. PubMed ID: 34956203
[TBL] [Abstract][Full Text] [Related]
5. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.
Fitzhugh CD; Cordes S; Taylor T; Coles W; Roskom K; Link M; Hsieh MM; Tisdale JF
Blood; 2017 Oct; 130(17):1946-1948. PubMed ID: 28887325
[TBL] [Abstract][Full Text] [Related]
6. Survival of transfused red blood cells from a donor with alpha-thalassemia trait in a recipient with sickle cell disease.
Yee MEM; Covington ML; Zerra PE; McCoy JW; Easley KA; Joiner CH; Bryksin J; Francis RO; Lough CM; Patel N; Kutlar A; Josephson CD; Roback JD; Stowell SR; Fasano RM
Transfusion; 2024 Jun; 64(6):1109-1115. PubMed ID: 38693059
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
8. Ex Vivo Activation of Red Blood Cell Senescence by Plasma from Sickle-Cell Disease Patients: Correlation between Markers and Adhesion Consequences during Acute Disease Events.
Chadebech P; Bodivit G; Di Liberto G; Jouard A; Vasseur C; Pirenne F; Bartolucci P
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34208829
[TBL] [Abstract][Full Text] [Related]
9. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR
Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586
[TBL] [Abstract][Full Text] [Related]
10. Management of a patient with sickle cell disease and multiple red blood cell alloantibodies in preparation for a hematopoietic stem cell transplantation.
Cigna M; Leiva-Torres GA; Baillargeon N; Yanez JC; Robitaille N
Transfusion; 2024 Mar; 64(3):554-559. PubMed ID: 38205646
[TBL] [Abstract][Full Text] [Related]
11. Measurement of post-transfusion red blood cell survival kinetics in sickle cell disease and β-Thalassemia: A biotin label approach.
Gerritsma JJ; van der Bolt N; van Bruggen R; Ten Brinke A; van Dam J; Guerrero G; Vermeulen C; de Bruin S; Vlaar APJ; Biemond BJ; Nur E; van der Schoot E; Fijnvandraat K;
Transfusion; 2022 Oct; 62(10):1984-1996. PubMed ID: 35916478
[TBL] [Abstract][Full Text] [Related]
12. Mathematical calculation of lifespan of transfused RBCs in sickle cell disease patients.
Kim J; Usmani A; De Simone N; Sarode R
Transfus Apher Sci; 2018 Feb; 57(1):46-49. PubMed ID: 29196100
[TBL] [Abstract][Full Text] [Related]
13. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.
Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S
Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248
[TBL] [Abstract][Full Text] [Related]
14. Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease.
Leonard A; Furstenau D; Abraham A; Darbari DS; Nickel RS; Limerick E; Fitzhugh C; Hsieh M; Tisdale JF
Blood Adv; 2023 Jan; 7(2):227-234. PubMed ID: 36240296
[TBL] [Abstract][Full Text] [Related]
15. Sickle Cell Trait Increases Red Blood Cell Storage Hemolysis and Post-Transfusion Clearance in Mice.
Osei-Hwedieh DO; Kanias T; Croix CS; Jessup M; Xiong Z; Sinchar D; Franks J; Xu Q; M Novelli E; Sertorio JT; Potoka K; Binder RJ; Basu S; Belanger AM; Kim-Shapiro DB; Triulzi D; Lee JS; Gladwin MT
EBioMedicine; 2016 Sep; 11():239-248. PubMed ID: 27523807
[TBL] [Abstract][Full Text] [Related]
16. Is Severity Score Associated With Indication for Hematopoietic Stem Cell Transplantation in Individuals With Sickle Cell Anemia?
Flor-Park MV; Ozahata MC; Moura ICG; Blatyta P; Kelly S; Oliveira CDL; Capuani L; Belisário AR; Carneiro-Proietti ABF; Araujo AS; Loureiro P; Maximo C; Rodrigues DOW; Mota RA; Sabino E; Custer B; Rocha V;
Transplant Cell Ther; 2022 Oct; 28(10):708.e1-708.e8. PubMed ID: 35788087
[TBL] [Abstract][Full Text] [Related]
17. Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe.
Gluckman E; Cappelli B; Scigliuolo GM; De la Fuente J; Corbacioglu S
Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):181-188. PubMed ID: 32201153
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends.
Shenoy S
Hematology Am Soc Hematol Educ Program; 2011; 2011():273-9. PubMed ID: 22160045
[TBL] [Abstract][Full Text] [Related]
19. Stable renal function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation.
Pedersen SJV; Monagel DA; Mammen C; Lewis VA; Guilcher GMT; Bruce AA
Pediatr Blood Cancer; 2020 Sep; 67(9):e28568. PubMed ID: 32672896
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.
Furstenau D; Peer CJ; Hughes TE; Uchida N; Tisdale J; Hall OM; Figg WD; Hsieh M
Pharmacotherapy; 2022 Jan; 42(1):14-22. PubMed ID: 34669981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
